hrp0089p2-p245 | Growth & Syndromes P2 | ESPE2018

Clinical Review of Seven Patients Affected with 49,XXXXY Syndrome

Sanchez Jacobo Perez , Collado Raquel Corripio , Escofet Concepcion , Brun Carme , Gabau Elisabeth

Introduction: 49,XXXXY polysomy incidence is about 1 per 85000 to 100000 male births. As a rare condition with medical problems affecting different systems it should be evaluated under a multidisciplinary approach. We have reviewed the clinical characteristics of patients with this anomaly from all the country who contacted the program for evaluation.Methods: In 2016 we started a multidisciplinary program for the care of patients with sex chromosomal ane...

hrp0094p2-197 | Fat, metabolism and obesity | ESPE2021

Triponderal mass index for the categorisation of childhood obesity on the basis of 58.364 observations of 7.792 patients

Corripio Raquel , Alder Lorna , Perez Jacobo , Sanchez-Garvin Dunia , Rivera Josefa ,

Introduction: childhood obesity constitutes a relevant problem of public health. Body mass index (BMI) is the most used anthropometric parameter for its definition: >2 z-score deviation (SD) according to age and sex for reference charts. Recent studies have proposed triponderal mass index (TMI) to identify metabolic risk by obesity. TMI presents the advantage to be a constant value simplifying the calculations.Aims: determine the use...

hrp0086rfc15.6 | Late Breaking | ESPE2016

Safety of GH in Paediatrics: The GeNeSIS Prospective Observational Study Experience between 1999 and 2015 (NCT01088412)

Blum Werner , Child Christopher , Chrousos George , Cummings Elisabeth , Deal Cheri , Hasegawa Tomonobu , Holterhus Paul-Martin , Jia Nan , Lawrence Sarah , Linglart Agnes , Loche Sandro , Maghnie Mohamad , Sanchez Jacobo Perez , Polak Michel , Predieri Barbara , Richter-Unruh Annette , Rosenfeld Ron , Tajima Toshihiro , Yeste Diego , Yorifuji Tohru

Background: Although GH’s safety profile since 1987 is good, concerns remain regarding cancer (CA) risk, and French SAGhE data indicated increased mortality and cerebrovascular disease (CVD) in certain GH-treated patients (pts).Objective and hypotheses: To evaluate key safety outcome incidence in GH-treated pts of all short stature diagnoses (dx) who participated in GeNeSIS (1999–2015, 30 countries).Methods: Pt history/ca...